Patents Assigned to Taiwan Liposome Company
-
Patent number: 11147881Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.Type: GrantFiled: January 7, 2019Date of Patent: October 19, 2021Assignees: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
-
Patent number: 10980798Abstract: Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.Type: GrantFiled: July 3, 2019Date of Patent: April 20, 2021Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Pei Kan, ChiaHung Hung, Keelung Hong, Yun-Long Tseng, Yung-Hsu Chan
-
Publication number: 20190216932Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.Type: ApplicationFiled: January 7, 2019Publication date: July 18, 2019Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
-
Patent number: 10350294Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.Type: GrantFiled: March 6, 2018Date of Patent: July 16, 2019Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
-
Patent number: 10322086Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.Type: GrantFiled: September 5, 2017Date of Patent: June 18, 2019Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
-
Patent number: 10286076Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.Type: GrantFiled: March 6, 2018Date of Patent: May 14, 2019Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
-
Patent number: 10220095Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.Type: GrantFiled: May 31, 2017Date of Patent: March 5, 2019Assignees: TAIWAN LIPOSOME COMPANY, LTD, TLC BIOPHARMACEUTICALS, INCInventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
-
Patent number: 10058616Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.Type: GrantFiled: February 8, 2013Date of Patent: August 28, 2018Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
-
Patent number: 9789062Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.Type: GrantFiled: July 5, 2013Date of Patent: October 17, 2017Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
-
Publication number: 20170266295Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.Type: ApplicationFiled: May 31, 2017Publication date: September 21, 2017Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
-
Patent number: 9700511Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.Type: GrantFiled: March 15, 2014Date of Patent: July 11, 2017Assignees: TLC Biopharmaceuticals, Inc., Taiwan Liposome Company, Ltd.Inventors: Pei Kan, Yun-Long Tseng, Han Chun Ou
-
Publication number: 20140287025Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: April 9, 2014Publication date: September 25, 2014Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
-
Publication number: 20140193486Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: March 7, 2014Publication date: July 10, 2014Applicants: TLC Biopharmaceuticals, Inc., Taiwan Liposome CompanyInventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
-
Publication number: 20140135357Abstract: The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.Type: ApplicationFiled: November 12, 2013Publication date: May 15, 2014Applicants: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.Inventors: Yun-Long TSENG, Keelung HONG, Min-Wen KUO
-
Publication number: 20090081121Abstract: The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject.Type: ApplicationFiled: September 25, 2008Publication date: March 26, 2009Applicants: National Health Research Institute, National Yang Ming University, Taiwan Liposome Company, Ltd.Inventors: Gann Ting, Yun-Long Tseng, Jun-Jen Liu, Hsin-Ell Wang, Jeng-Jong Hwang, Yi-Ching Lu, Wan-Chi Lee
-
Publication number: 20080234376Abstract: An emulsion composition includes prostaglandin E1 (PGE1), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE1. Embodiments of the emulsion composition include an effective amount of PGE1, about 1% to about 30% (w/w) of a pharmaceutically acceptable oil as an oil base based on the weight of the emulsion composition, about 1% to about 30% (w/w) of a phospholipid with a high purity based on the weight of the oil base, about 1.6% to about 40% (w/w) of a non-proton-providing surfactant based on the weight of the oil base, and the balance of the emulsion composition being water.Type: ApplicationFiled: August 15, 2007Publication date: September 25, 2008Applicants: TAIWAN LIPOSOME COMPANY (A TAIWAN CORPORATION), TLC Biopharmaceuticals, Inc. ( a United States business entity)Inventors: Yi-Fong LIN, Pei KAN, Keelung HONG
-
Publication number: 20080118500Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: November 16, 2007Publication date: May 22, 2008Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen Liu, Yun-Long Tseng, Sheue-Fang Shih, Luke S.S. Guo, Keelung Hong